Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer
- PMID: 26036635
- PMCID: PMC4652991
- DOI: 10.18632/oncotarget.3933
Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer
Abstract
Tanshinone is the liposoluble constituent of Salia miltiorrhiza, a root used in traditional herbal medicine which is known to possess certain health benefits. Although it is known that tanshinones, including tanshinone I (T1), tanshinone IIA (T2A), and cryptotanshinone (CT), can inhibit the growth of lung cancer cells in vitro, the mechanism under which they act is still unclear. AURKA, an oncogene, encodes a serine-threonine kinase which regulates mitotic processes in mammalian cells. Here, we reported that tanshinones mediate AURKA suppression partly through up-regulating the expression of miR-32. We found that tanshinones could inhibit cell proliferation, promote apoptosis, and impede cell-cycle progression, thus performing an antineoplastic function in non-small cell lung cancer (NSCLC). Additionally, we demonstrated that tanshinones attained these effects in part by down-regulating AURKA, corroborating previous reports. Our results showed that in NSCLC, similar effects were obtained with knock-down of the AURKA gene by siRNA. We also verified that AURKA was the direct target of miR-32. Collectively, our results demonstrated that tanshinones could inhibit NSCLC by suppressing AURKA via up-regulating the expressions of miR-32 and other related miRNAs.
Keywords: AURKA; miRNA; non-small cell lung cancer; tanshinone.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
Similar articles
-
Tanshinone T1/T2A inhibits non-small cell lung cancer through Lin28B-let-7-BORA/MYC regulatory network.Gene. 2025 Jan 30;935:149058. doi: 10.1016/j.gene.2024.149058. Epub 2024 Oct 29. Gene. 2025. PMID: 39481768
-
Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.Mol Carcinog. 2013 Jul;52(7):535-43. doi: 10.1002/mc.21888. Epub 2012 Mar 2. Mol Carcinog. 2013. PMID: 22389266 Free PMC article.
-
Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.Int J Cancer. 2011 Sep 1;129(5):1042-52. doi: 10.1002/ijc.25678. Epub 2010 Nov 3. Int J Cancer. 2011. PMID: 20848589 Free PMC article.
-
Tanshinones: sources, pharmacokinetics and anti-cancer activities.Int J Mol Sci. 2012 Oct 22;13(10):13621-66. doi: 10.3390/ijms131013621. Int J Mol Sci. 2012. PMID: 23202971 Free PMC article. Review.
-
Tanshinones: An Update in the Medicinal Chemistry in Recent 5 Years.Curr Med Chem. 2021;28(14):2807-2827. doi: 10.2174/0929867327666200521124850. Curr Med Chem. 2021. PMID: 32436817 Review.
Cited by
-
Effects of tanshinones mediated by forkhead box O3a transcription factor on the proliferation and apoptosis of lung cancer cells.Oncol Lett. 2019 Jan;17(1):450-455. doi: 10.3892/ol.2018.9530. Epub 2018 Oct 1. Oncol Lett. 2019. PMID: 30655786 Free PMC article.
-
Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis.Int J Biol Sci. 2019 Apr 22;15(5):1072-1079. doi: 10.7150/ijbs.31277. eCollection 2019. Int J Biol Sci. 2019. PMID: 31182926 Free PMC article.
-
MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.Oncogenesis. 2017 Aug 21;6(8):e372. doi: 10.1038/oncsis.2017.50. Oncogenesis. 2017. PMID: 28825720 Free PMC article.
-
LINC00958 promotes bladder cancer carcinogenesis by targeting miR-490-3p and AURKA.BMC Cancer. 2021 Oct 26;21(1):1145. doi: 10.1186/s12885-021-08882-6. BMC Cancer. 2021. PMID: 34702201 Free PMC article.
-
An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen).Explor Target Antitumor Ther. 2020;1(3):153-170. doi: 10.37349/etat.2020.00010. Epub 2020 Jun 29. Explor Target Antitumor Ther. 2020. PMID: 36046197 Free PMC article. Review.
References
-
- Fujioka N, Bitterman PB. Molecular targeted therapy in lung cancer. Minn Med. 2012;95:38–41. - PubMed
-
- Malgieri S, Feliciano S, Bosso D, Federico P, Palmieri G, De Placido S, Di Lorenzo G, Buonerba C. Non-small cell lung cancer: from targeted therapy to tailored therapy. Expert Opin Pharmacother. 2012;13:1817–1819. - PubMed
-
- Petrosyan F, Daw H, Haddad A, Spiro T. Targeted therapy for lung cancer. Anticancer Drugs. 2012;23:1016–1021. - PubMed
-
- Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345–1359. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
